Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine
Molecules · 31.05.2024 · 29 (11) · 2584
DOI: 10.3390/molecules29112584 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, online erschienen am 31.05.2024. Verfasst von Chinedu O Egwu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Medical Research Council, London School of Hygiene and Tropical Medicine, Banjul 220, The Gambia. Hauptthemen laut MEDLINE: Drug Delivery Systems, Nanostructures, Nanomedicine. Die Arbeit wurde bisher 118-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization.
Abstract (Originalsprache)
There is a myriad of diseases that plague the world ranging from infectious, cancer and other chronic diseases with varying interventions. However, the dynamism of causative agents of infectious diseases and incessant mutations accompanying other forms of chronic diseases like cancer, have worsened the treatment outcomes. These factors often lead to treatment failure via different drug resistance mechanisms. More so, the cost of developing newer drugs is huge. This underscores the need for a paradigm shift in the drug delivery approach in order to achieve desired treatment outcomes. There is intensified research in nanomedicine, which has shown promises in improving the therapeutic outcome of drugs at preclinical stages with increased efficacy and reduced toxicity. Regardless of the huge benefits of nanotechnology in drug delivery, challenges such as regulatory approval, scalability, cost implication and potential toxicity must be addressed via streamlining of regulatory hurdles and increased research funding. In conclusion, the idea of nanotechnology in drug delivery holds immense promise for optimizing therapeutic outcomes. This work presents opportunities to revolutionize treatment strategies, providing expert opinions on translating the huge amount of research in nanomedicine into clinical benefits for patients with resistant infections and cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Medical Research Council, London School of Hygiene and Tropical Medicine, Banjul 220, The Gambia.
- Medical Biochemistry Department, College of Medicine, Alex-Ekwueme Federal University Ndufu-Alike, P.M.B. 1010, Ikwo 482131, Nigeria.
- Protein Structure-Function and Research Unit, School of Molecular and Cell Biology, Faculty of Science, University of the Witwatersrand, Braamfontein, Johannesburg 2050, South Africa.
- Anatomy Department, College of Medicine, Alex-Ekwueme Federal University Ndufu-Alike, P.M.B. 1010, Ikwo 482131, Nigeria.
- World Health Organization, United Nations House Plot 617/618 Central Area District, P.M.B. 2861, Abuja 900211, Nigeria.
- Society for Family Health, 20 Omotayo Ojo Street, Allen, Ikeja 100246, Nigeria.
ORCID-Profile: Chinedu O Egwu, Chinyere Aloke, Jennifer Adaeze Chukwu, Chukwuemeka O Okoro
Förderung
- World Health Organization
Zitieren
APA
Egwu, C. O., Aloke, C., Onwe, K. T., Umoke, C. I., Nwafor, J., Eyo, R. A., Chukwu, J. A., Ufebe, G. O., Ladokun, J., Audu, D. T., Agwu, A. O., Obasi, D. C., & Okoro, C. O. (2024). Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules, 29(11), 2584. https://doi.org/10.3390/molecules29112584
Vancouver
Egwu CO, Aloke C, Onwe KT, Umoke CI, Nwafor J, Eyo RA, et al. Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine. Molecules. 2024;29(11):2584. doi:10.3390/molecules29112584
BibTeX
@article{Egwu2024,
author = {Egwu, Chinedu O and Aloke, Chinyere and Onwe, Kenneth T and Umoke, Chukwunalu Igbudu and Nwafor, Joseph and Eyo, Robert A and Chukwu, Jennifer Adaeze and Ufebe, Godswill O and Ladokun, Jennifer and Audu, David Tersoo and Agwu, Anthony O and Obasi, David Chukwu and Okoro, Chukwuemeka O},
title = {Nanomaterials in Drug Delivery: Strengths and Opportunities in Medicine},
journal = {Molecules},
year = {2024},
volume = {29},
number = {11},
pages = {2584},
doi = {10.3390/molecules29112584}
}
EUVIMED